Photo from wikipedia
Omalizumab (OMZ) is a monoclonal anti‐immunoglobulin E antibody used in patients with chronic spontaneous urticaria (CSU). The data about using OMZ during the coronavirus disease 19 (COVID‐19) pandemic are limited.… Click to show full abstract
Omalizumab (OMZ) is a monoclonal anti‐immunoglobulin E antibody used in patients with chronic spontaneous urticaria (CSU). The data about using OMZ during the coronavirus disease 19 (COVID‐19) pandemic are limited. The aim of this study was to evaluate the status of having COVID‐19 and relationships between COVID‐19, vaccination, and urticaria symptoms of CSU patients on OMZ.
Keywords:
spontaneous urticaria;
patients chronic;
retrospective evaluation;
covid pandemic;
chronic spontaneous
Journal Title: Journal of Cosmetic Dermatology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Cosmetic Dermatology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!